Edition:
United Kingdom

People: CytomX Therapeutics Inc (CTMX.OQ)

CTMX.OQ on NASDAQ Stock Exchange Global Select Market

9.40USD
5:02pm BST
Change (% chg)

$-0.59 (-5.91%)
Prev Close
$9.99
Open
$9.95
Day's High
$10.02
Day's Low
$9.36
Volume
62,386
Avg. Vol
172,530
52-wk High
$27.23
52-wk Low
$9.36

Gluck, Frederick 

Mr. Frederick Gluck serves as an Independent Director of the company. Mr. Gluck has served as a member of our board of directors since September 2010 and was a member of the board of directors of CytomX Therapeutics, LLC until September 2010. Mr. Gluck previously served as a member of the board of directors of Amgen, Inc. from February 1998 to October 2011. He has also served as founding chairman of the board and CEO of our predecessor company, CytomX, LLC, from 2006 to 2008. Mr. Gluck currently serves as chairman of the board of Cynvenio Biosystems, Inc., a private company that was spun off from CytomX in 2008, where he has served on the board since 2008. He also currently serves as co-chairman of the board of TrueVision Systems Inc., a private company where he has served on the board since 2007. Mr. Gluck served as a consultant to McKinsey & Company, Inc., an international management-consulting firm (“McKinsey”), from July 1998 to July 2003. Prior to that, he was Vice Chairman and Director of Bechtel Group, Inc., an engineering, construction and project management company, from 1995 to July 1998. Mr. Gluck is a former partner of McKinsey, where he served from 1967 to 1995. Between 1988 and 1994, he was the Managing Director of McKinsey. He also serves as a director of the Foundation Board of the University of California, Santa Barbara, the Kavli Institute of Theoretical Physics and The New York Presbyterian Hospital (Emeritus). Mr. Gluck was the presiding director of the Hospital Corporation of America. Mr. Gluck received his B.S. from Manhattan College and M.S. from New York University in electrical engineering. We believe that Mr. Gluck is qualified to serve on our board of directors due to his extensive management experience, substantial experience in the life sciences industry and his well-known expertise in corporate strategy.

Basic Compensation

Total Annual Compensation, USD 47,500
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 114,848
Fiscal Year Total, USD 162,348

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Sean McCarthy

3,213,340

Debanjan Ray

1,563,120

Nick Galli

--

Leslie Robbins

--

W. Michael Kavanaugh

1,382,260

Rachel Humphrey

1,539,700
As Of  31 Dec 2017